The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.
Study Goal
The researchers aimed to review advances in understanding iron homeostasis in chronic kidney disease (CKD) and explore potential improvements in anemia management for CKD patients.
Results Summary
The abstract highlights dysregulated iron homeostasis in CKD and its role in anemia, noting that iron supplementation is a key treatment but lacks rigorous large-scale trials. Genetic and animal model studies provide insights into iron regulation and potential therapeutic advances.
Population
Chronic kidney disease (CKD) patients
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Iron supplementation | decrease | anemia | CKD patients | - | is one cornerstone of anemia management | #1 |
Iron supplementation | neutral | - | CKD patients | - | has not been rigorously studied | #2 |
Iron is essential for most living organisms but iron excess can be toxic. Cellular and systemic iron balance is therefore tightly controlled. Iron homeostasis is dysregulated in chronic kidney disease (CKD) and contributes to the anemia that is prevalent in this patient population. Iron supplementation is one cornerstone of anemia management in CKD patients, but has not been rigorously studied in large prospective randomized controlled trials. This review highlights important advances from genetic studies and animal models that have provided key insights into the molecular mechanisms governing iron homeostasis and its disturbance in CKD, and summarizes how these findings may yield advances in the care of this patient population.